Gut hormones and the control of appetite

Obesity is the main cause of premature death in the UK. Worldwide its prevalence is accelerating. It has been hypothesized that a gut nutriment sensor signals to appetite centres in the brain to reduce food intake after meals. Gut hormones have been identified as an important mechanism for this. Ghr...

Full description

Saved in:
Bibliographic Details
Published in:Trends in endocrinology and metabolism 2004-08, Vol.15 (6), p.259-263
Main Authors: Small, Caroline J., Bloom, Stephen R.
Format: Article
Language:English
Subjects:
Animals
Appetite Regulation - physiology
Biological and medical sciences
Cholecystokinin - physiology
Cholecystokinin - therapeutic use
Fundamental and applied biological sciences. Psychology
Gastrointestinal Hormones - physiology
Gastrointestinal Hormones - therapeutic use
Ghrelin
Glucagon - physiology
Glucagon - therapeutic use
Glucagon-Like Peptide 1
Glucagon-Like Peptides - physiology
Glucagon-Like Peptides - therapeutic use
Humans
Leptin - physiology
Leptin - therapeutic use
Obesity - physiopathology
Obesity - prevention & control
Oxyntomodulin
Pancreatic Polypeptide - physiology
Pancreatic Polypeptide - therapeutic use
Peptide Fragments - physiology
Peptide Fragments - therapeutic use
Peptide Hormones - physiology
Peptide Hormones - therapeutic use
Peptide YY - physiology
Peptide YY - therapeutic use
Protein Precursors - physiology
Protein Precursors - therapeutic use
Vertebrates: endocrinology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obesity is the main cause of premature death in the UK. Worldwide its prevalence is accelerating. It has been hypothesized that a gut nutriment sensor signals to appetite centres in the brain to reduce food intake after meals. Gut hormones have been identified as an important mechanism for this. Ghrelin stimulates, and glucagon like peptide-1, oxyntomodulin, peptide YY (PYY), cholecystokinin and pancreatic polypeptide inhibit, appetite. At physiological postprandial concentrations they can alter food intake markedly in humans and rodents. In addition, in obese humans fasting levels of PYY are suppressed and postprandial release is reduced. Administration of gut hormones might provide a novel and physiological approach in anti-obesity therapy. Here, we summarize some of the recent advances in this field.
ISSN:1043-2760
1879-3061
DOI:10.1016/j.tem.2004.06.002